ALK-Abelló stock went into the earnings release under pressure, down roughly 20% over the past three months, yet the latest numbers tell a more resilient story. The company just posted trailing twelve month revenue of DKK 6,561m and earnings from continuing operations of DKK 1,280m, with a net profit margin near 19.5%. The key question for you now is whether that profit profile justifies a P/E of about 36x in a sector where many peers trade at far lower multiples. The rest of the earnings will test that premium.
Is ALK-Abelló’s 36x P/E a justified premium, or a sign that the stock is priced for perfection already? See how the current multiples line up against cash flows and sector peers in the valuation analysis for ALK-Abelló
Q2 2026 Earnings Summary
- Revenue TTM (to Q1 2026 vs. TTM to Q4 2025): DKK 6,561m vs. DKK 6,312m (up 4.0%)
- Net Income TTM (to Q1 2026 vs. TTM to Q4 2025): DKK 1,280m vs. DKK 1,197m (up 6.9%)
- Basic EPS TTM (to Q1 2026 vs. TTM to Q4 2025): DKK 5.78 vs. DKK 5.40 (up 7.0%)
- Net Profit Margin TTM (to Q1 2026 vs. prior year): 19.5% vs. 16.4% (higher margin)
Prefer simple, visual charts instead of a dense wall of earnings figures and P/E ratios? View ALK-Abelló’s full valuation picture at a glance in the interactive company report for ALK-Abelló.
Evaluating ALK-Abelló’s Growth Story Against Q2 Delivery
The bullish narrative around ALK-Abelló is that allergy tablets, neffy and the pipeline can sustain broad-based growth while supporting strong margins and cash generation. Q2 results go a long way toward proving that. Tablets passed DKK 1b in quarterly revenue with 22% growth, helped by pediatric approvals for ACARIZAX and ITULAZAX and double digit growth across Europe, North America and International markets. That lines up with the claim of a larger addressable patient pool rather than just price or one-off factors.
The anaphylaxis story is earlier, yet Jext and neffy together sit inside a 26% rise in anaphylaxis and other products, with neffy still small but expanding into 10 markets. EBIT growth of 19% on roughly stable margins in the 25 to 28% range and free cash flow of DKK 889m in H1, with guidance now above DKK 1b, support the view that higher R&D and launch spend is so far being funded from internal momentum rather than eroding profitability.
Compare ALK-Abelló’s solid tablet growth, expanding neffy footprint and near 19.5% net margin with how the stock closed at DKK 209.0 on 20 August 2026. Then consider whether that 36x P/E still lines up with institutional expectations. See the consensus price target analysis for ALK-AbellóALK-Abelló Bears Still Waiting For Clear Cracks
The key bearish claim on ALK-Abelló is that growth is over reliant on high margin tablets and neffy momentum, so any slowdown in patient demand or mix shift into lower margin products would cap profitability and strain cash generation just as capex and R&D step up. Q2 does not fully support that. Tablets are still growing faster than SCIT and partner markets, and the EBIT margin remains in the mid 20s even with higher capacity and launch costs. Free cash flow is strong enough for guidance to move above DKK 1b.
Where the bears still have a case is on milestones missed around anaphylaxis adoption and policy risk. neffy uptake is described as modest, with the U.K. rollout delayed and revenues concentrated in a few markets, so the hoped for rapid shift away from auto injectors is not yet visible. The 2027 German rebate hike also keeps medium term margin risk unresolved.
With EBIT margins in the mid 20s and free cash flow guidance above DKK 1b, investors still need to verify how secure ALK-Abelló’s balance sheet really is. Check the full financial health analysis of ALK-Abelló stock.Stay Ahead Of Your Next Move
If ALK-Abelló’s mix of tablet growth, neffy rollout and a 19.5% net margin has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. After you decide to build or adjust a position, use the Portfolio Command Center to cut through market noise and focus on the most important updates to your holdings. For ongoing context around ALK-Abelló and similar stocks, tap into the Community to see how other investors are thinking about the same risks and opportunities. This approach can help you spot potential catalysts and red flags earlier and stay a step ahead of the wider market.
Seeking Alternatives Beyond ALK-Abelló?
Fresh stock ideas move fast. Some are building breakout momentum while others stay under the radar for now. Spot them before the crowd reacts, then act with a clear plan.
- Track income that keeps working while prices move by scanning carefully vetted high yield candidates in the 432 dividend fortresses before payouts or share prices are repriced.
- Target durable growth stories with balance sheets that can absorb shocks by reviewing the curated list of solid balance sheet and fundamentals stocks (431 results) while these opportunities are still flying under most radars.
- Consider potential AI momentum early by checking the hand picked 76 profitable AI stocks that aren't just burning cash before valuations are influenced by later money chasing the same stories.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com